Unjha Formulations Ltd

Unjha Formulations has released its financial results for the quarter ending December 2024, showing a flat performance for Q3 FY24-25. While the Profit After Tax for the nine-month period increased significantly, half-yearly net sales declined, highlighting a mixed financial outlook for the company.

Unjha Formulations, a microcap pharmaceutical company, saw its stock price reach an all-time high of Rs. 39 on November 10th, 2024. Despite underperforming the sector, the stock has shown a positive trend and is currently trading above its moving averages. With a significant increase in the past year, the company remains a promising player in the pharmaceutical industry.

Unjha Formulations, a microcap pharmaceutical company, has reported a positive financial performance in the second quarter of fiscal year 2024-2025. The company's PAT has increased and it has generated a higher operating cash flow. However, its PBDIT and PBT for the quarter are the lowest in the last five quarters, indicating a negative trend in the near term. MarketsMOJO has given a 'Hold' call for the company's stock.

Unjha Formulations, a microcap pharmaceutical company, reached an all-time high stock price of Rs.39 on November 9th, 2024. Despite underperforming the sector by -9.82%, the stock has been rated 'Hold' by MarketsMOJO. It has shown volatility with an intraday high of Rs.39 and low of Rs.33.3. The stock is currently trading above its moving averages, indicating a positive trend.

Unjha Formulations, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on November 8th, 2024. The stock has outperformed the sector by 4.91% and gained 13.52% in the last 3 days. According to MarketsMOJO, the stock is currently rated as 'Hold' and has shown a positive trend, trading higher than its moving averages. The company's strong financial performance and growth potential have attracted investor attention, but it is important to conduct thorough research before making any investment decisions.

Unjha Formulations, a microcap pharmaceutical company, has gained attention in the stock market with its share price reaching an all-time high of Rs. 39 on November 8, 2024. According to MarketsMOJO, the current recommendation for the stock is 'Hold' and it has been outperforming the sector by 5.27%. The company's stock price has also been consistently higher than its moving averages, indicating a positive trend.

On November 5th, Unjha Formulations reached a 52-week high of Rs. 37.03, outperforming the sector by 5.03% and trading higher than its moving averages. Unjha Formulations, a microcap pharmaceutical company, has reached a 52-week high of Rs. 37.03 on November 5th, 2024. With a consecutive 3-day gain and a 23.33% increase in returns, the stock has been performing well in the market. It has also outperformed the sector and is currently trading higher than its moving averages.

Unjha Formulations, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high on November 5th, 2024. The company has outperformed the sector by 2.63% and has shown a 1-year performance of 98.23%, indicating strong growth and potential in the pharmaceutical industry.

Unjha Formulations, a microcap pharmaceutical company, has reached a new milestone as its stock price hit a 52-week high on November 4th, 2024. According to MarketsMOJO, the stock is currently rated as 'Hold' and has outperformed the sector by 7.83%. With a consecutive 2-day gain and trading above its moving averages, the company shows strong growth potential and has outperformed the market in the past year.

Unjha Formulations, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high on November 4th, 2024. The stock has outperformed the sector by 10.14% and has been on a consecutive gain for the past two days, with a 15.67% increase in returns. It is currently trading above its moving averages and has shown a significant growth of 93.21% in the past year. Investors can consider holding onto their stocks, but should do thorough research and consult with a financial advisor before making any investment decisions.

Unjha Formulations, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its positive results in the last three quarters, with a high operating cash flow and growth in net sales. Technical indicators also suggest a bullish trend, and the company has attractive valuation and strong performance in the market. However, its long-term fundamental strength and debt-servicing ability may be a concern. Investors are advised to hold and monitor closely.

Unjha Formulations, a microcap pharmaceutical company, has reported positive growth in its financial performance for the quarter ending June 2024. The company's net sales have increased by 26.97% year on year, with the highest operating cash flow in the last three years. Its profitability and earnings per share have also shown a positive trend. MarketsMOJO has given a 'Sell' call for the company's stock based on these results.

Unjha Formulations, a microcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to weak long-term fundamental strength and concerns about debt servicing. The company's expensive valuation and falling profits are also factors. However, recent positive results and a track record of market-beating performance may offer some hope. Non-institutional investors and outperformance against BSE 500 should also be considered.

Unjha Formulations, a microcap pharmaceutical company, received a 'Hold' rating from MarketsMOJO on June 18, 2024. The company reported a 64.96% growth in net sales and a higher PAT of Rs 0.21 crore in March 2024. The stock has shown a 7.54% return since June 11, 2024, supported by factors such as MACD and Bollinger Band. However, its long-term fundamentals and valuation may be a concern, with a weak CAGR growth in operating profits and high price to book value. Investors are advised to hold onto their positions and monitor the company's performance closely.

Unjha Formulations, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on May 23, 2024. The stock has consistently outperformed its sector by 5.25% and is currently trading higher than its moving averages. With a remarkable 122.59% increase in the past year, the company shows strong potential for growth in the pharmaceutical industry.

Unjha Formulations, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high on May 23, 2024. With a 'Hold' rating from MarketsMOJO, the company's stock is currently trading close to its 52-week high and has outperformed the Sensex in the past year, showcasing its potential for growth in the market.

The stock has shown consecutive gains for the past two days, reaching a 52-week high and trading above its moving averages, indicating a positive trend.

Unjha Formulations, a microcap pharmaceutical company, has reported a positive performance in the quarter ending March 2024 with a score improvement from 6 to 8. The company's net sales have grown by 64.96% year on year, indicating a strong sales trend. Its profitability has also improved, with a higher PAT in just half a year compared to the previous 12-month period. MarketsMOJO has given a 'Hold' call for the company's stock, suggesting investors monitor its future performance before making any investment decisions.

Unjha Formulations, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on May 17, 2024. The stock has outperformed the sector by 4.94% and gained 53.52% in the last 6 days. The company's consistent positive trend and strong potential in the pharmaceutical industry make it a promising investment option.